We hereby attaching you the board meeting outcome
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.6 pts more than Nifty Microcap 250 and 3.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Virupaksha Organics Limited has successfully completed its open offer and taken control as the new promoter of Oxygenta Pharmaceutical Ltd, effective June 20, 2025. As a result, the entire board was reconstituted: 6 new directors were appointed — 2 Executive (Mr. Chandra Mouliswar Reddy Gangavaram, Mr. Balasubba Reddy Mamilla), 1 Non-Executive (Mrs. Vedavathi Gangavaram), and 3 Independent (Mr. Veera Reddy Arava, Mr. Sidda Reddy Kanuparthi, Mrs. Sharvari Swapnil Shinde). All 6 outgoing directors — 3 Executive Directors (Mr. Sunil Vishram Chawda, Mrs. Sravani Reddy Gantla, Mr. Kanuganti Raghavender Rao) and 3 Independent Directors (Mr. Bharath Reddy Guntuku, Mrs. Padmaja Surapureddy, Mrs. Aakanksha Sachin Dubey) — resigned citing the takeover and change in management. Mr. Sai Sudhakar Vankineni continues as Managing Director & CFO, and all board committees (Audit, Nomination & Remuneration, Stakeholders' Relationship) were also reconstituted.
Shareholders should expect a potential shift in strategic direction under the new promoter Virupaksha Organics Limited. The board now comprises pharma industry veterans, which may indicate a renewed focus on the core pharmaceutical business.